Ganetespib, another second-generation HSP90 inhibitor has shown promising clinical activity (clinical benefit rate of 60%) in combination with paclitaxel and trastuzumab (clinical benefit rate was 60%) in heavily pretreated patients with HER2-positive metastatic BC [31]. The gene discussed is ERBB2; the disease is breast cancer.